Press release
Primary Biliary Cholangitis Treatment Market Valued at USD 1.2 Billion in 2023; Projected to Grow Significantly Through 2034 Driven by Anticipated Pipeline Drugs | DelveInsight
Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast – 2034
DelveInsight's "Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights into the PBC market, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
The primary biliary cholangitis market size was USD 1.2 billion across the 7MM in 2023, which is forecasted to increase steadily from 2024 to 2034. Furthermore, the US accounted for the largest PBC market share. This trend is expected to continue in the forecasted period, due to a larger patient pool, better disease awareness, and favourable reimbursement policies.
Download the Primary Biliary Cholangitis Market Forecast Report to understand which factors are driving the Primary Biliary Cholangitis market @ Primary Biliary Cholangitis Market Trends [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report provides detailed epidemiological data segmentation covering total diagnosed prevalent cases, gender-specific diagnosed prevalent cases, and age-specific diagnosed prevalent cases of primary biliary cholangitis across the 7MM during the study period (2020-2034).
According to the primary biliary cholangitis epidemiology contained in the report, the US accounted for the largest proportion of diagnosed prevalent PBC cases among the 7MM in 2023. Furthermore, the epidemiology model reveals a significantly higher prevalence among females compared to males across all markets, attributable to genetic predisposition, hormonal influences, and environmental factors. Among European nations, Germany reported the highest burden, followed by Italy and the UK. The data also indicates that PBC predominantly affects individuals aged 40-70 years, reinforcing the importance of age-targeted screening and treatment strategies.
Discover evolving trends in the Primary Biliary Cholangitis patient pool forecasts @ Primary Biliary Cholangitis Epidemiological Analysis [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current primary biliary cholangitis treatment landscape has been historically dominated by ursodeoxycholic acid (UDCA) as the cornerstone first-line therapy, with obeticholic acid (OCALIVA) from Intercept Pharmaceuticals serving as the second-line option for patients with inadequate response to or intolerance of UDCA. However, the therapeutic paradigm has experienced significant evolution in 2024 with the FDA granting accelerated approvals to two novel treatments: Elafibranor (IQIRVO) in June 2024 by Genfit/Ipsen and Seladelpar (LIVDELZI) in August 2024 by Gilead Sciences. Both therapeutics represent innovative approaches targeting peroxisome proliferator-activated receptors, offering new mechanisms to address the complex primary biliary cholangitis pathophysiology.
The primary biliary cholangitis clinical trials market is demonstrating robust activity, with several promising candidates advancing through the development pipeline. Saroglitazar Magnesium by Zydus Therapeutics, a dual PPAR alpha/gamma agonist with the FDA Fast Track and Orphan Drug designations, shows substantial potential in addressing both cholestasis and metabolic aspects of PBC. A Phase IIb/III trial (NCT05133336) is ongoing to further evaluate its dual PPAR alpha/gamma agonism targeting metabolic and inflammatory pathways.
GlaxoSmithKline's Linerixibat, an IBAT inhibitor currently in Phase III trials, targets the debilitating pruritus associated with PBC. Additionally, COUR Pharmaceuticals' CNP-104 secured FDA Orphan Drug Designation in January 2025, positioning it as potentially the first disease-modifying treatment for PBC by inducing tolerance to pathogenic activated PDC-E2 T-cells that drive bile duct inflammation.
Discover evolving trends in the Primary Biliary Cholangitis treatment landscape @ Primary Biliary Cholangitis Recent Developments [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite these significant advancements, the PBC market faces several challenges, including insufficient disease awareness among healthcare providers and patients, complex diagnostic processes resulting in under-recognition, and affordability barriers to innovative treatments. Addressing these obstacles will require comprehensive educational initiatives, streamlined diagnostic pathways, and creative pricing strategies to improve treatment accessibility.
Furthermore, safety concerns continue to emerge, as evidenced by the FDA's recent identification of serious liver injury cases in non-cirrhotic PBC patients treated with obeticholic acid. This new safety concern was announced in a Drug Safety Communication in December 2024, following a review of postmarket clinical trial data, highlighting the ongoing need for vigilant safety monitoring of both established and emerging therapies.
The primary biliary cholangitis competitive landscape is evolving rapidly, with several key players actively involved in therapeutic development and commercialization. Some of the pharmaceutical companies active in this landscape include Gilead Sciences (NASDAQ: GILD), Intercept Pharmaceuticals (NASDAQ: ICPT), CymaBay Therapeutics (NASDAQ: CBAY), COUR Pharmaceuticals, Teva Pharmaceutical (NYSE: TEVA), Mylan, AbbVie (NYSE: ABBV), Glenmark Pharmaceuticals (NSE: GLENMARK), Allergan, Eli Lilly (NYSE: LLY), Novartis (NYSE: NVS), Pfizer (NYSE: PFE), Roche (SWX: ROG), Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), AstraZeneca (NASDAQ: AZN), GlaxoSmithKline (NYSE: GSK), Takeda (NYSE: TAK), Amgen (NASDAQ: AMGN), Boehringer Ingelheim, Dr. Reddy's (NYSE: RDY), Amneal (NASDAQ: AMRX), Alnylam (NASDAQ: ALNY), Ionis (NASDAQ: IONS), Arrowhead (NASDAQ: ARWR), CureVac (NASDAQ: CVAC), Sangamo (NASDAQ: SGMO), Calliditas Therapeutics (NASDAQ: CALT), NGM Biopharmaceuticals (NASDAQ: NGM), Bluebird Bio (NASDAQ: BLUE), Intellia (NASDAQ: NTLA), Albireo, TARGET PharmaSolutions, Genfit (NASDAQ: GNFT), and Ascletis Pharma, among others.
Looking ahead, DelveInsight forecasts the primary biliary cholangitis market will witness accelerated growth driven by the continued uptake of newly approved therapies and the potential introduction of pipeline candidates addressing unmet needs. The integration of biomarker-guided treatment approaches and combination regimens is anticipated to optimize therapeutic outcomes, while ongoing research into disease-modifying interventions may fundamentally transform the treatment paradigm. As the understanding of PBC pathophysiology advances, the market is poised for further innovation, with the ultimate goal of improving quality of life and long-term outcomes for patients living with this challenging autoimmune liver condition.
Table of Contents
1. Key Insights
2. Executive Summary of Primary Biliary Cholangitis
3. Primary Biliary Cholangitis Competitive Intelligence
4. Primary Biliary Cholangitis: Market Overview at a Glance
5. Primary Biliary Cholangitis: Disease Background and Overview
6. Patient Journey
7. Primary Biliary Cholangitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cholangitis Unmet Needs
10. Key Endpoints of Primary Biliary Cholangitis Treatment
11. Primary Biliary Cholangitis Marketed Products
12. Primary Biliary Cholangitis Emerging Therapies
13. Primary Biliary Cholangitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Primary Biliary Cholangitis
17. KOL Views
18. Primary Biliary Cholangitis Market Drivers
19. Primary Biliary Cholangitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Primary Biliary Cholangitis Pipeline Insight [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Primary Biliary Cholangitis Pipeline Insight provides comprehensive insights about the Primary Biliary Cholangitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Primary Biliary Cholangitis companies, including Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Calliditas Therapeutics, Dr Falk Pharma, Mirum Pharmaceuticals, and GlaxoSmithKline, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-biliary-cholangitis-treatment-market-valued-at-usd-12-billion-in-2023-projected-to-grow-significantly-through-2034-driven-by-anticipated-pipeline-drugs-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Treatment Market Valued at USD 1.2 Billion in 2023; Projected to Grow Significantly Through 2034 Driven by Anticipated Pipeline Drugs | DelveInsight here
News-ID: 4008301 • Views: …
More Releases from ABNewswire
Harmony Grove Recovery Now Accepts Most Major Health Insurances for Addiction Tr …
Harmony Grove Recovery in San Diego now accepts Cigna, Aetna, GEHA, Tricare, Blue Shield and more for addiction treatment.
San Diego, CA - September 3, 2025 - Harmony Grove Recovery, a premier provider of luxury addiction and mental health treatment, is proud to announce that it now accepts most major health insurance plans for its comprehensive addiction services in San Diego. With coverage for insurers including Cigna, Aetna, GEHA, Tricare, Blue…
PilateSocks officially launches in Melbourne: Australia's grippiest, most stylis …
Melbourne, Australia - Aussieowned PilateSocks is thrilled to launch its first full collection of premium pilates socks designed to elevate every practice with maximum grip socks, breathable comfort and ethical flair.
Built for the women who seek stability and style, PilateSocks combines functionfirst design with a brand that truly cares for people, planet and the Pilates community.
PilateSocks introduces gamechanging rubberised soles that offer nonslip confidence on any mat, tower or barre.…
Lucintel Forecasts the Global Epitaxial Wafer in Compound Semiconductor Market t …
The future of the epitaxial wafer in the global compound semiconductor market looks promising with opportunities in the industrial, energy & power, defense/security, digital economy, transport, healthcare, consumer electronic, and space sectors. Epitaxial wafer in the global compound semiconductor market is expected to reach an estimated $3.3 billion by 2031
According to a market report by Lucintel, the future of the global epitaxial wafer in compound semiconductor market looks promising with…
Lucintel Forecasts the Global 6G Wireless Technology Market is expected to grow …
The future of the global 6G wireless technology market looks promising with opportunities in the artificial intelligence, automation & robotics, internet of things, and VR and AR markets. The global 6G wireless technology market is expected to grow with a CAGR of 73% from 2025 to 2031. The major drivers for this market are increasing demand for higher bandwidth, growing demand for low latency
According to a market report by Lucintel,…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
